A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
NCT05903118
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
480
Enrollment
INDUSTRY
Sponsor class
Conditions
SARS-CoV-2
Interventions
BIOLOGICAL:
RBMRNA-176
OTHER:
Placebo
Sponsor
Argorna Pharmaceuticals Co., LTD